Clinical Trial Update: Safety, Feasibility and Cost-effectiveness of Genotype-directed Individualized Dosing of Fluoropyrimidines [NA]

View source ↗

Summary

A completed trial evaluating genotype-directed individualized dosing of fluoropyrimidines for cancer, assessing safety, feasibility, and cost-effectiveness.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Neoplasms | NA | Status: COMPLETED